4MOVING-BIOTECH
2.7.2024 07:31:32 CEST | Business Wire | Press release
4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma specializing in immuno-inflammation and osteoarthritis, is pleased to announce the appointment of Luc Boblet as Chief Executive Officer. The company, having successfully completed its Phase I clinical trial and a preparatory in silico Phase 2 analysis, looks to Luc Boblet's seasoned expertise in biotech entrepreneurship and strategic development to guide the forthcoming stages of clinical proof of concept and early market access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701233556/en/
Luc Boblet, CEO OF 4Moving Biotech (Photo: Business Wire)
Luc Boblet, a biotech entrepreneur with two decades of experience, joins 4MB following his tenure at Egle Therapeutics, where his leadership was essential in advancing novel immunotherapies and securing a robust Series A funding backed by a big pharma strategic alliance. His previous roles included founding and leading companies such as H-IMMUNE - acquired by HiFiBIO - and Pathoquest, where he excelled in driving innovation, closing fundraising and forging strategic partnerships as instrumental catalyst of growth.
"Luc's appointment comes at a turning point for 4Moving Biotech as we have concluded a milestone Phase I trial for our leading drug candidate and are advancing strategic discussions with the FDA, toward potential accelerated approval" said Revital Rattenbach, founder and CEO of 4P-Pharma and co-founder of 4Moving. "His track record in steering biotech ventures and his strategic approach to partnerships will be invaluable as we advance our clinical programs and explore opportunities for pharma co-development and partnership."
As CEO of 4Moving Biotech, Luc Boblet's immediate focus will be on overseeing the design and implementation of the development strategy for the upcoming Phase II clinical trials, as well as cultivating partnerships that align with the company's vision for growth and patient access to innovative treatments.
Luc Boblet, CEO of 4Moving Biotech said: "The opportunity to lead 4Moving Biotech at this juncture is one that is aligned with my commitment to bringing pioneering therapies for untreated severe diseases. The company's progress in drug development and the potential to significantly improve patient outcomes in osteoarthritis is a strong foundation for future success. I am looking forward to applying my experience in corporate strategy business development to deliver our value proposal and establish meaningful partnerships."
About 4Moving Biotech
4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to developing advanced first in class therapies in the field of immuno-inflammation and osteoarthritis. With a commitment to improving patient care, 4MB is actively engaged in the clinical development of novel treatments poised to enhance quality of life for patients worldwide.
Biography of Luc Boblet, CEO of 4Moving Biotech.
Luc Boblet is a serial biotech entrepreneur with 20 years of experience in entrepreneurship, business development, corporate finance and early drug development. Luc is coming from Egle Therapeutics, spin out of Institut Curie dedicated to developing novel Regulatory T-cells based immunotherapies for oncology and autoimmune diseases, he has co-founded in early 2020. As a founding CEO, he built Egle Tx with a vision to become a game changer in the field of Tregs immunomodulation catalyzed by strategic alliance with Takeda Pharmaceutical and backed by 45M€ Series A from a high-quality syndicate of renowned international investors. Before creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun out of French Nuclear Agency (CEA), developing novel anti-check-point immunotherapies against T-effector and Tregs for oncology. He paved H-IMMUNE corporate path through partnerships with Pierre Fabre Laboratories and Norther Biologics and have exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up company spun out of Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S.
From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.
He started his career in technology transfer, consulting in finance and business development for toxicogenomics R&D. Luc Boblet holds a biotech engineering degree, master’s degree in Virology and has been trained as a PhD in Virology from University Paris VII.
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701233556/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release
IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release
BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom